Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 92,93€(+31,03%). Der Median liegt bei 92,93€(+31,03%).
Kaufen | 16 |
Halten | 4 |
Verkaufen | 1 |
Scoring-Modelle
Dividenden-Strategie | 3 / 15 |
HGI-Strategie | 9 / 18 |
Levermann-Strategie | -4 / 13 |
News
Encompass Health announces promotion of Patrick Tuer to newly established COO position
BIRMINGHAM, Ala. , April 24, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced the promotion of Patrick Tuer from group president to the newly established position of chief operating officer (COO), effective immediately.» Mehr auf prnewswire.com
Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers
Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer ( “COO” ) and Jessica Kourniaktis, DPhil , as Director of Communications of the Company. Ms. Kandziora is a seasoned executive with over 20 years of leadership experience across the biopharma, financial, and consulting sectors, bringing a rare trifecta of administrative acumen, people-centered leadership, and organizational insight to her role as COO of Helix BioPharma. Her long-standing relationship with the Company brings invaluable continuity and deep institutional knowledge to this role, having supported corporate strategy, transformation, and stakeholder engagement for Helix in Europe and North America. She previously served as Corporate Secretary of Helix (2017–2019) and as a strategic consultant to the Company's leadership and Board in the years leading up to her appointment. Alongside these roles, she spent 15 years as an independent Asset Manager, advising clients on corporate development, intellectual property, and strategic investments—primarily in the biopharma space. Ms. Kandziora began her career in the financial industry in 2003, leading complex international projects across Germany, Austria, Italy, and Liechtenstein, and consulting for wealth managers, trustees, and investment funds with a focus on biotechnology, technology, and raw materials. A polyglot with a strong foundation in finance and compliance, Ms. Kandziora holds a Diploma in Management and Hospitality from the WIFI Academy of Applied Sciences in Austria, and is a certified Vocational Trainer in Liechtenstein. She has also completed advanced compliance training with the Institute for Compliance and Quality Management (ICQM) and the Association for Quality Assurance of Financial Services (VQF), reinforcing her ability to navigate complex regulatory and governance environments with confidence and clarity.» Mehr auf thenewswire.com
LUCA APPOINTS RAMON MENDOZA INTERIM COO
VANCOUVER, BC , April 24, 2025 /PRNewswire/ - Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) reports that Mr. Armando Alexandri has stepped down from his role as Chief Operating Officer of the Company to pursue a new opportunity.» Mehr auf prnewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Jan. 2025 | |
---|---|---|
Umsatz | 930,98 Mio | 7,96% |
Bruttoeinkommen | 637,13 Mio | 20,02% |
Nettoeinkommen | 100,65 Mio | 33,92% |
EBITDA | 175,64 Mio | 27,10% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 14,18 Mrd€ |
Anzahl Aktien | 199,98 Mio |
52 Wochen-Hoch/Tief | 98,52€ - 61,20€ |
Dividenden | Nein |
Beta | 1,01 |
KGV (PE Ratio) | 39,18 |
KGWV (PEG Ratio) | 7,02 |
KBV (PB Ratio) | 2,00 |
KUV (PS Ratio) | 4,12 |
Unternehmensprofil
The Cooper Companies, Inc. entwickelt, produziert und vertreibt zusammen mit ihren Tochtergesellschaften Kontaktlinsen. Das Unternehmen ist in zwei Segmenten tätig, CooperVision und CooperSurgical. Das Segment CooperVision bietet sphärische Linsen, einschließlich Linsen, die Kurz- und Weitsichtigkeit korrigieren, sowie torische und multifokale Linsen, die Linsen zur Korrektur von Sehproblemen wie Astigmatismus, Alterssichtigkeit, Kurzsichtigkeit, Augentrockenheit und Augenermüdung in Amerika, Europa, dem Nahen Osten, Afrika und dem asiatisch-pazifischen Raum umfassen. Das Segment CooperSurgical konzentriert sich auf die Familien- und Frauengesundheitspflege, die medizinische Geräte, Fruchtbarkeit, Genomik, Diagnostik und Empfängnisverhütung für medizinisches Fachpersonal und Patienten weltweit anbietet. Es bietet chirurgische und Büroprodukte, einschließlich PARAGARD, Uterusmanipulatoren, Retraktoren, Verschlussprodukte, Point-of-Care-Produkte, LEEP-Produkte, Endosee sowie Illuminate- und Fötus-Kissen; Fruchtbarkeitsprodukte und -dienstleistungen, wie Fruchtbarkeitsverbrauchsmaterial und -ausrüstung sowie Embryo-Optionen und Präimplantations-Gentests. The Cooper Companies, Inc. wurde 1958 gegründet und hat seinen Hauptsitz in San Ramon, Kalifornien.
Name | Cooper Companies |
CEO | Albert G. White III |
Sitz | San Ramon, ca USA |
Website | |
Industrie | Gesundheitswesen: Ausstattung und Produkte |
Börsengang | |
Mitarbeiter | 16.000 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | COO |
Düsseldorf | CP6.DU |
Frankfurt | CP6.F |
London | 0I3I.L |
München | CP6.MU |
SIX | CP6.SW |
London Stock Exchange | 0I3I.L |
NASDAQ | COO |
Assets entdecken
Shareholder von Cooper Companies investieren auch in folgende Assets